This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
Baxter International (BAX) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of -1.67% and -0.28%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
BAX Stock Falls Following Q2 Earnings & Sales Miss, '25 EPS View Down
by Zacks Equity Research
Baxter misses on Q2 earnings and sales, trims full-year EPS view, and posts weaker gross margin. Shares slide nearly 9% pre-market.
Baxter (BAX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Baxter (BAX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Stay Ahead of the Game With Baxter (BAX) Q2 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for Baxter (BAX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
InMode (INMD) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
InMode (INMD) delivered earnings and revenue surprises of +9.30% and +0.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Baxter Q2 Preview: Can Core Segments Deliver Another Solid Quarter?
by Zacks Equity Research
BAX aims for modest Q2 growth as core segments build on Q1 momentum and margin gains stabilize after recent recovery.
FMS Stock Likely to Gain on New Optimization Plan FME Reignite
by Zacks Equity Research
Fresenius Medical Care unveils FME Reignite, targeting one billion euros in cost savings, tech upgrades and enhanced shareholder returns.
BAX Stock May Rise Following the Launch of FDA-Approved Hemopatch Pad
by Zacks Equity Research
Baxter launches Hemopatch Sealing Hemostat, an FDA-approved collagen pad designed for effective hemostasis and sealing in both open and minimally invasive surgeries.
BAX Stock Gains Following Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Baxter reports better-than-expected first-quarter results. However, the company's gross margin contracts. Shares rise in pre-market.
Baxter (BAX) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Baxter (BAX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Baxter (BAX) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Baxter (BAX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
by Harshit Gupta
The medical device industry is growing fast in 2025, but faces supply and trade issues. Major companies to report earnings on May 1, stay tuned!
Will BAX's Q1 Earnings Improve Following Transformation Completion?
by Zacks Equity Research
Baxter's first-quarter results are likely to reflect the favorable impact of kidney care sales. Growth in infusion therapies, pharmaceuticals and patient support systems to continue.
BAX Stock Declines Despite Latest Product Launch Boosting Patient Care
by Zacks Equity Research
Baxter aims to promote enhanced patient care through the evolution of its latest product, which enables direct accessibility in the operating room.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Baxter Stock Likely to Gain Following the Introduction of Voalte Linq
by Zacks Equity Research
At the 2025 HIMSS Global Healthcare Conference, BAX unveils its Voalte Linq device, powered by Scotty assistant, a voice-activated technology.
Company News for Feb 21, 2025
by Zacks Equity Research
Companies in The News Are: LNG,W,BILI,BAX
BAX Stock Surges Following Q4 Earnings & Sales Beat, Margins Decline
by Zacks Equity Research
Baxter reports better-than-expected fourth-quarter results. However, the company's gross and operating margins contract. Shares rise in pre-market.
Baxter (BAX) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Will BAX's Q4 Earnings Reflect Its Efforts to Counter Headwinds?
by Zacks Equity Research
Baxter might have faced fourth-quarter hurdles from Hurricane Helene. However, it expects growth in infusion therapies, pharmaceuticals and patient support systems to have driven recovery.
Countdown to Baxter (BAX) Q4 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Baxter (BAX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
New Strong Sell Stocks for January 27th
by Zacks Equity Research
BASFY, BNPQY and BAX have been added to the Zacks Rank #5 (Strong Sell) List on January 27, 2024.
Alcoa and Baxter in the Box have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Alcoa and Baxter in the Box have been highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Baxter (BAX)
by David Bartosiak
The recent earnings trend has been troubling. Can the company turn it around next year?
Baxter Stock May Gain Following Five New Injectable Product Launches
by Zacks Equity Research
BAX launches five new injectible products in the United States, thus further strengthening its U.S Pharmaceuticals business segment.